Organon & Co.
NYSEOrganon & Co. heads into the back half of June with its most interesting tension in months: short sellers are cutting exposure at a meaningful clip even as the consensus view on the Street remains cautious. Short interest has dropped sharply — down more than 10% over the past week to 6.9% of the free float, from a recent peak near 8% in late May. The move represents a genuine…
Snapshot as of 2 Jul 2026
Organon & Co. heads into the back half of June with its most interesting tension in months: short sellers are cutting exposure at a meaningful clip even as the consensus view on the Street remains cautious. Short…
Organon & Co. arrives at its April 30 Q1 print riding one of the most dramatic recoveries in the pharmaceutical space — up 125% in a month and 42% in the past week alone — yet the analyst community remains firmly in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OGN — free to start on ORTEX.
Sign up for free →Open OGN on ORTEX